CompanyWeek Q&A: Harry Moser, Founder and President of the Reshoring Initiative

Harry Moser’s Reshoring Initiative measures the degree to which U.S. companies are reshoring jobs and attracting foreign direct investment (FDI). With interest and activity heightened from the pandemic, trade wars, and other factors, I reached out for an update.

As with any conversation today about reshoring manufacturing jobs, we talked extensively about China, and a troubling undercurrent that may profoundly affect America’s industrial future.

CompanyWeek: Your 2020 final reshoring numbers are out, and the data indicates, “Reshoring and FDI job announcements for 2020 were 160,649, bringing the total jobs announced since 2010 to over 1 million (1,057,054).” Put those numbers in context for us?

Harry Moser: We track reshoring which is done by U.S. companies, and FDI — foreign direct investment — which is done by foreign-headquartered companies, and we typically report on the total of the two trends. In 2010, the total reshoring that year was 6,000 [jobs], and there was a continuous uptrend until 2017, which was the peak year so far, with about 185,000 jobs driven that year by business enthusiasm for the tax and regulatory reform. And then things fell off in 2018 and 2019, primarily due to the trade war. Companies didn’t know what the rules were going to be, what tariffs were going to apply to what products, from what countries, for how many years, and they said, “Let’s wait and see what happens.”

Then, in 2020, we had COVID, and reshoring surged dramatically. The total in 2020 was about 160,000 jobs, the second highest on record. So to have that happen during a pandemic was incredibly good, and the fact that reshoring was so strong, shows that companies are taking care of “home.” They realize — for U.S. companies at least — that their main market is still the U.S., and therefore they’re putting their investments in the U.S., where FDI has of course slowed down.

From a different perspective, this is the first time that reshoring has been stronger than FDI in about the last seven or eight years. A million jobs have been announced, and given that it will take a year or two from the announcement until the hires are actually made, we think that conservatively, 700,000 or so jobs have actually been created. To put that in perspective, that’s more than the actual employment increase since 2010, meaning that if we hadn’t had the reshoring, manufacturing employment would have gone down instead of up since 2010, and the 700,000 is about 6 percent of total manufacturing employment.

CW: So, what does 2021 look like? It would seem that, given the disruptions in the supply chain companies are experiencing, we’d see an acceleration in the trend?

HM: Our forecast is for 200,000 total jobs in 2021, the reason being that basic driving factors are still in place: companies are still very much aware of COVID, Chinese wages continue to rise — about a week ago it was announced China’s year-over-year consumer price increase was about nine percent — and their business costs continue to go up dramatically, so they are somewhat less competitive overall.

There’s also significant talk about “decoupling.” One of the top China experts [in Asia], Eamon McKiney, believes that China is so mad at the U.S. — because of Trump, because of Taiwan, Huawei and other things — that China, at some point in time, will not allow any of its companies to ship anything to the U.S. They will totally decouple. I’ve heard other experts echo this sentiment, maybe not as strong a view, but obviously, if it happens, there would be a lot of reshoring happening very quickly!

But even the possibility it could happen, that companies could be totally cut off from their Chinese sources, not in two years but bam, like that, should be enough to get companies to pull back the most important, hardest to replace, the most critical items here, but if not here, then Mexico or someone else they can count on.

CW: On the other hand, that seems to run counter to China’s demographic challenge, that China has to create millions of jobs each year to continue to support middle class growth. Many of those jobs are in manufacturing companies making products for American brands.

HM: I would not agree with all of that. Actually China’s working age population, say 18 to 65, is dropping at the rate of about three million per year. Why? Because of the one-child policy that went into place, what, maybe 40 years ago? Even though they’ve relaxed that policy, today the Chinese are saying, “Life’s good with one child! We’re not going to have three or four kids.” A lot has been written about the question, “Will China become rich before it gets too old?” and the demographics, the increase of the over-65 population, is frightening for them. Increasingly, there will be fewer people to replace the retiring population.

What they really need to do — obviously they shouldn’t cut us off completely — is to get their own people to consume more. They save, roughly, 40 percent of their income where Americans normally save 3 or 4 percent of their income. That’s why the Chinese have so much money to invest in factories, in highways, in everything else. They need to get their population to spend more, to become the consumers that Americans are, and absorb that extra capacity they’re shipping to the U.S. Conversely, Americans need to work more and save more, and create the productive capacity that we’re now getting from China.

CW: Just to stay on that point. It does seem, though, it would be a bit of a “cut your nose off to spite your face” approach. Decoupling would force the U.S. to strengthen its industrial base. The U.S. would become a more capable industrial competitor and global threat to China.

Moving on: Do you see, as others do, the entry of China into the WTO as a low-water mark for U.S. manufacturing? Can we coexist with China as an equal trading partner?

HM: Under the current terms of trade, we cannot coexist with almost anybody. The U.S. has a trade deficit with nine of its top 10 trading partners. The exception is the U.K., which is a basket case for manufacturing, relative to its glorious manufacturing past, and the U.S. has followed the same decline.

If you look at what China did, as they grew, they produced products that otherwise would have been produced in Mexico, in Taiwan, South Korea, Japan, India, Malaysia, wherever. But China invested the most, they were the hardest working, bid the lowest prices, whatever, and they got the contracts. Right now we have a $900 billion trade deficit. If China did not exist at all, I still think we’d have a $750 billion trade deficit!

All these countries have industrial policies that combine things like currency, taxes, training and education, investment in research and facilities, et cetera. We don’t. I call it a “de-industrialization” policy. If you want to destroy your manufacturing, you’d do what we do: Every poor country you want to help, you’d give them favored-nation status to import products to the U.S. with lower duties than they give us; you’d spend billions protecting the rest of the world from pirates and terrorism; you’d allow your universities to flourish in liberal arts and your skilled workforce to decline; and you wouldn’t have a value-added tax to protect your key industries. If you want manufacturing to disappear, that’s what you’d do. And we’ve done that.

CW: Well said. How do the numerous recent initiatives strike you — legislation in the Senate and reference to a new industrial policy?

HM: I refer to them as “the Biden supply-chain effort.” And I call those things “tourniquets,” because our country has ignored these things for so long, because we’re in such a dangerous place of losing key industries, it’s certainly necessary to make these investments at a national level, and 10 years from now will be too late.

On the other hand, it’s not clear that you can save the patient that way.

CW: How so?

HM: The simplest thing to understand is chips. Taiwan Semiconductor is talking about one big chip plant in the U.S. Intel is talking about two, and the U.S. government is going to subsidize a few more, and soon we’ll be making two or three times as many chips as we do now. But the cost of making them, no matter the subsidies of the factories, will be higher because of higher labor costs here than in China or Taiwan; the costs of building the factories will be higher. So you’re going to have chips that are more expensively made here than made there.

Then, who’s going to consume the chips? Where do the chips go? Into cell phones, televisions, game boxes, servers, whatever — and almost all those things are made in China! We’ll be a high-cost producer of chips, dependent on China to buy all the excess chips above and beyond what we can consume. So instead of depending on them for chips, we’re going to depend on them being a customer for our chips.

My conclusion is that yes, we have to invest in chips, you can’t just drop out of that game, but we need to make the U.S. competitive by currency, by skilled workforce, by VAT, and motivate companies here to start making the products to consume the chips. Otherwise, we won’t be in much better shape than we are today.

Bart Taylor is publisher of CompanyWeek. Contact him at btaylor@companyweek

Colorado Leaders Q&A: Marcia Coulson, President of Eldon James

We’ve reported how Colorado lags in large manufacturing-related infrastructure investments, but despite another subpar year relative to other states, a flurry of recent activity lately demonstrates how things could be changing.

Last week alone, three significant new factories were announced, in three growth industries powering Colorado manufacturing. York Space Systems‘ new “mega-center” in Denver, Meati‘s 76,000-square-foot production facility, and Eldon James‘ sprawling new 100,000-square-foot medical-device factory are all eye-opening additions to the region’s manufacturing ecosystem.

I caught up with Eldon James President and 2019 Colorado Manufacturing Woman of the Year Marcia Coulson for a brief conservation last week.

CompanyWeek: You’ve been busy! Can you provide an update?

Marcia Coulson: Well, the pandemic has been a catalyst for us. We never anticipated this, but beginning last spring we started supplying millions of parts for the ventilator project. We pulled out all our stock and began manufacturing as fast as we could to keep up with the demand. We got to work with ventilator companies throughout the world building ventilators. Ford actually wrote us a really nice letter thanking us for being part of their ventilator project. That felt really good for our company.

Then it shifted to producing the vaccines, and we supply a lot of components for the single-use systems that they use for vaccines, including the large plastic bags that they grow drugs in, instead of the stainless-steel systems. They migrated from stainless steel because it takes about a week to clean between different drug lots, and they’re always concerned about cross-contamination from one lot to the next.

So they’ve migrated to these large plastic bags, and we make connectors that are welded into the bags, the tubing that’s connected to those fittings, and all the fittings downstream, including our new SeriesLock quick-disconnect product, that are used in the pharmaceutical industry as well.

We were able to supply components for Pfizer, Moderna, and J&J, and now we’re working on the Sputnik project and supplying a lot of parts for their vaccine program. It’s been exciting to play a small part in such an important initiative.

CW: Or a large part, as it were. I’m curious: You seemed so well-positioned, with a network in place, to plug right in to a national vaccine effort. How did that come about?

MC: We’ve been working more with pharmaceutical companies the past 15 years. When we built our first clean room, it was to manufacture products for that market. So it didn’t happen overnight; we’ve been working with these companies for that amount of time, building products for that industry. We’ve actually migrated to where 85 percent of our sales today goes to the pharmaceutical, medical device, and laboratory supply markets. We actually changed our business, as we were once also focused on automotive and industrial products. Thankfully, now 85 percent of what we manufacture goes to those three markets.

CW: Do you see that mix sustaining? I know there was interest in the beverage industry.

MC: Yeah, we’re not putting as much emphasis on the beverage industry. The pharma market requires quality, so they don’t necessarily beat you up on price. The beverage industry is very competitive, and there’s not as much margin in the products. It’s a fun industry! Just not one we’re putting a lot of focus on.

CW: Speaking of price, I picked up on something in our last conversation that stuck with me, that of the need, in your view, for targeted tariffs, or VATs, to enable domestic manufacturers to compete with Asian imports on price. Given what’s happened the past year, do you still see a need for measures to level the playing field?

MC: Well, we still need support with tariffs. However, one thing I think the pandemic has pointed out is that hospitals are starting to realize that maybe we don’t want all of our drugs and medical devices made in China. And they’ve finally caught on to that!

Take ventilators: Companies were manufacturing ventilators like crazy, but providers didn’t realize that every ventilator that was being used needed two filters — one to protect the ventilator and one to protect the patient — and those have to be changed on a daily basis. I had hospitals in New Jersey that were basically in tears because New York absorbed all the filters that were available in the market for the ventilators. There were none left for hospitals in New Jersey.

We realized that all of the filter media was made in China. We were done when we ran through the inventory. Add to that, for the manufacturers of the filters, the Chinese market was the top priority. I’m sure we lost some people because we couldn’t replace the filters on the ventilators. There’s no statistics to prove it, but it’s a scary thing, that all the filter media manufacturing went to China, and we couldn’t get it when we needed it.

We actually had a filter we were trying to get through the FDA so that we could manufacture filters here, but we just couldn’t get any traction as they were giving all their attention to approving ventilator manufacturers. Fortunately, as providers realized that fewer patients need to be on ventilators, things quieted down a little bit.

CW: But hospitals got the message?

MC: I do think it was a huge red flag for hospitals: “Maybe we oughta break this up and not buy the least expensive product.”

And as manufacturers, we can’t compete with China. There’s no way we can offer the same product at the same price. Medical devices do take humans to build and assemble and package and label and work in the regulatory side.

And something interesting has also come to light: We sell to China, and I know there are companies there that do what we do. To my customers, I’m like, “Why aren’t you buying Chinese products?” We’ve been told, “Well, we prefer in China for our medical devices to buy the higher-quality products made in the U.S., and we sell the U.S. our lower-quality products.”

What they’re saying is: “What we manufacture in China isn’t good enough for us, but it is for the U.S.”

We need more help from the government to equal out the playing field, to encourage hospitals to buy American-manufactured products, whether it’s a bonus program, or a tax-credit program to where they’re incentivized to to buy. Hospitals are under great pressure to make a profit; they’re going to be encouraged to buy the least expensive products.

CW: National policy issues aside, what can be done at a local level to encourage more manufacturing?

MC: We have a hard time hiring employees, so we need to encourage people to go to work, to go back to work. I’m not sure what we’ve created here — it should be interesting to see how it plays out. But we’re incredibly thankful to our great team.

CW: How many employees do you currently have?

MC: Between the two facilities — WilMarc and Eldon James — we’re at about 100.

CW: You’re doing a lot with 100 employees.

MC: Keep in mind we automate just as much as we possibly can so that we can compete on a global basis. We’re working really hard to automate. The new facility will be highly automated — but we still need people! They just don’t have to do the work equipment can do.

CW: Again, congratulations — and we’ll see you in September at the Colorado Manufacturing Awards Alumni gathering!

Bart Taylor is publisher of CompanyWeek. Reach him at btaylor@companyweek.com.